Mydecine Innovations Group Inc. (OTCMKTS:NLBIF) has announced the filing of a provisional patent application in the US Patent and Trademark Office by its wholly-owned subsidiary NeuroPharm Inc. The patent covers the composition of matter claims about a psychedelic therapy enhancer for treating some psychiatric disorders and includes enhancing PTSD treatments.
Patent cover psychedelic therapy enhancer
This provisional patent covers the active ingredient in psilocybin, which causes psychedelic effects and enhancers, which reduced the enzymatic breakdown of psilocin. The psychedelic enhancer results in improved psychedelic experienced in PTSD treatment, whether by intensity per dose, intensity, or extension in time or a combination of both.
NeuroPharm develops natural health and psilocybin based PTSD and mental disorder treatments for the veteran community. The subsidiary collaborates with various strategic partners, and it is deploying research-based medicine in establishing psilocybin-based therapies. These treatments address the unmet needs of high-risk individuals. The company is focused on developing proprietary and unique technologies for treating various mental health disorders that veterans frequently experience. Some of the conditions include depression, anxiety, PTSD, panic disorders, addiction, and cluster headaches and migraines.
Mydecine delighted of patent filing
Mydecine CEO Josh Bartch said that the invention covered by the exciting provisional patent filing holds significant promise in treating various psychiatric disorders. Bartch said that through the reduction of the enzymatic breakdown of psilocin the company will enhance the therapeutic efficacy of psilocybin at low doses. This is because dose reduction conveys a wide range of benefits that include enhanced psychedelic experience, low costs of administration, and limiting non-therapeutic effects. This will, therefore, help advance Mydecine’s mission of developing and bringing to the market novel treatments that address a variety of mental health disorders that include depression, anxiety, and PTSD.
The company has been leveraging strategic partnerships with medical, scientific, clinical, and military organizations to develop psychedelic-based therapies and medicines for various disorders. The company, through its subsidiary, aims at delivering adaptive plant-based therapies to veterans to treat traumatic disorders.